Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

Bris­tol My­ers Squibb has seen set­back af­ter set­back for its chances to bring im­muno-on­col­o­gy block­buster Op­di­vo in­to new­ly di­ag­nosed brain can­cer pa­tients — a sort of holy grail for the field. De­spite hold­ing a slim hope Op­di­vo would turn around its chances, Bris­tol is ready to call it quits for now.

Bris­tol’s com­bo of Op­di­vo on top of stan­dard-of-care temo­zolo­mide plus ra­di­a­tion couldn’t beat place­bo in ex­tend­ing over­all sur­vival in pa­tients with new­ly di­ag­nosed MGMT-pos­i­tive glioblas­toma mul­ti­forme who pre­vi­ous­ly had their tu­mor sur­gi­cal­ly re­moved, the com­pa­ny said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER